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Background: Diazoxide (DZ) is an adenosine triphosphate potassium (KATP) channel opener that was first approved in the 1960’s, and used for 
decades to treat hyperinsulinemic hypoglycemia and hypertensive emergencies. DZ may provide cardio-protection through coronary vasodilatation 
and ischemic preconditioning. Reports suggest DZ may also improve lipid parameters, insulin sensitivity, and reduce body weight.
Method: Diazoxide Choline Controlled Release (DCCR) is a proprietary once daily DZ formulation. To test the hypothesis that DCCR lowers triglyceride 
(TG) levels in hypertriglyceridemic patients, this double-blind study randomized 90 subjects with baseline TG 200 - 650 mg/dL to placebo or DCCR 
tablets in dosages equivalent to 200 mg/day, 300 mg/day, or 400 mg/day DZ for 8 weeks. Subjects with glucose ≥ 126 mg/dL and/or HbA1C > 
6.5% were excluded. Nineteen subjects receiving steady doses of statin at baseline remained on statin throughout the study. The primary endpoint 
was the median percent change in TG.
Results: Compared to placebo, DCCR containing 200 mg DZ reduced median TG by 21.4% (p=0.0763), 300 mg by 30.1% (p=0.0003), and 400 mg 
by 32.1% (p<0.0001). In subjects with baseline TG ≥ 400 mg/dL (n=14), DCCR reduced median TG by 42.5%. DCCR showed non-significant, albeit 
consistent reductions in non-high density lipoprotein cholesterol and total cholesterol, with a modest rise in high density lipoprotein cholesterol. 
Mean low density lipoprotein cholesterol (LDL-C) levels did not increase. Among those with baseline LDL-C ≥ 160 mg/dL (n=23), DCCR reduced 
LDL-C by 9.2%. Lipid effects were generally similar among those with or without concomitant statin. DCCR increased median fasting glucose by 
12.4% (12 mg/dL) and HbA1C by 0.1%. Although weight did not change, DCCR also appeared to reduce waist circumference, blood pressure, liver 
enzymes, and homeostasis model assessment of insulin resistance.
Conclusion: DCCR was generally well tolerated; most adverse events were mild to moderate with no deaths or serious adverse events. Among 
previously reported favorable effects of DZ on cardiovascular risk factors, this study suggests DCCR significantly reduces TG without raising LDL-C 
levels.
